Herbal Epilepsy Studies Show Promise But Have Weak Reporting

What was studied

This paper reviewed randomized controlled trials of traditional Chinese herbal formulas that contain Bupleurum chinense (also called Chaihu) for people with epilepsy. The authors searched four databases through July 2025 and found 33 trials with a total of 2,464 participants.

The review looked at whether these herbal formulas were associated with changes in seizure frequency, seizure duration, overall treatment response, and adverse events. It also assessed how well the trials were reported and whether they described methods related to bias, such as randomization, allocation concealment, and blinding.

What they found

When the trial results were pooled together, Bupleurum-based formulas showed better results than antiepileptic drug monotherapy on several outcomes. The combined results found lower seizure frequency, shorter seizure duration, and better overall clinical efficacy in the herbal medicine groups. Reported adverse event rates were not significantly different between groups.

However, the review also found major problems in how the trials were done and reported. Reporting quality was rated as suboptimal overall. Very few trials described allocation concealment, and none mentioned blinding of participants or study personnel. Only 11 of the 33 trials systematically reported adverse events.

Limits of the evidence

This review cannot establish with confidence that Bupleurum-based formulas have effects as large as the pooled results suggest. Many of the included trials had weak methods or poor reporting, which raises the risk of biased results.

There was also very high variation between studies for seizure frequency and seizure duration, which means the trial results were not closely consistent with each other. The abstract does not provide details such as ages, epilepsy types, treatment length, or how similar the herbal formulas were across studies, so it is hard to know who the findings apply to most. Safety is also uncertain because most trials did not report adverse events carefully.

For families and caregivers

For families, this study suggests that some Bupleurum-containing herbal formulas are being studied for epilepsy and showed promising results in the included trials. But the evidence is not strong enough to be confident, because many of the trials were not designed or reported well.

This means the results are interesting but should be viewed cautiously. The review also does not fully answer safety questions, because adverse events were not systematically reported in most trials.

What to watch next

Stronger evidence would come from larger, rigorously conducted trials with clear randomization, better reporting, careful adverse event tracking, and adherence to CONSORT and CONSORT-CHM guidelines.

Terms in this summary

randomized controlled trial

A study where people are assigned by chance to different treatments so the groups can be compared more fairly.

meta-analysis

A method that combines results from multiple studies to look for an overall pattern.

allocation concealment

A way to keep researchers from knowing the next treatment assignment ahead of time, which helps prevent bias.

blinding

Keeping participants, clinicians, or researchers unaware of which treatment was given to reduce bias.

risk of bias

The chance that study methods could make the results look better or worse than the truth.

adverse events

Side effects or other unwanted medical problems that happen during treatment.

CONSORT

A set of guidelines for clearly reporting clinical trials.

traditional Chinese medicine

A medical system that includes herbal treatments and other approaches developed in China.